You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
20 July 2026 - Personalis Inc (Nasdaq: PSNL), a provider of advanced genomics for precision oncology, announced on Monday that it has agreed to be acquired by technology firm Tempus AI Inc (NASDAQ: TEM) in a transaction valued at approximately USD1.5...
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/JAK1 inhibitor being developed for autoimmune dise...
20 July 2026 - Evaxion A/S, a Denmark-based, clinical-stage TechBio company developing novel vaccines with its AI-Immunology platform, said on Friday that it will present three-year clinical efficacy data from its phase 2 trial with personalised canc...
20 July 2026 - Canada-based biotechnology company Arch Biopartners Inc (TSX-V:ARCH) (OTCQB:ACHFF) announced on Friday that it has engaged a US-based laboratory specialising in bioengineering to accelerate the company's pre-IND IL-32 chronic kidn...
20 July 2026 - UK biopharmaceutical company Ananda Pharma Limited announced on Friday that the first patient taking part in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's proprietary CBD-based drug candidate, in treatment...
17 July 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Thursday that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug des...
17 July 2026 - AI-native radiology company Raidium announced on Thursday the US launch of Raidium Read (R.Read), applying its AI-native imaging solution initially to oncology research centres.Raidium has already been deployed at Moffitt Cancer Center...